Rouen University Hospital
Rouen, France
NCT Number: NCT02295514
Despite major advances in the treatment and understanding of the pathophysiological mechanisms, mortality of severe sepsis remains high, ranging from 25 to 50%. With a prevalence > 20% in intensive care units, it is now in a population increasingly aging with many co-morbidities, a real public health problem. Thus, changes in treatment to physiological axes could change the prognosis of these patients. Protein Tyrosine Phosphatase 1B (PTP1B) is involved in the negative regulation of many cellular pathways such as the response to insulin, leptin and certain growth factors and endothelial nitric oxide production. PTP1B appears to be particularly involved in the control of endothelial function and insulin secretion. Under these conditions, encouraging results have been obtained in a model of insulin resistance (obesity, diabetes) and as part of pro-angiogenic therapy by inhibition of PTP1B on models of heart failure. Recent advances have broadened the pathophysiological implications of PTP1B conferring a potential role in the regulation of inflammatory processes. In an experimental model of septic shock (Inserm 1096), the investigators demonstrated a significant improvement in survival and cardiovascular function in genetically deficient mice PTP1B (PTP1B - / -). Finally, PTP1B is involved in the downregulation of the signaling pathway of insulin via a feedback phenomenon. Septic shock induces many changes in carbohydrate metabolism. These changes result in hyperglycemia associated with insulin resistance, an independent risk factor of morbidity and mortality. Taken together, these data suggest that the expression of PTP1B could be useful in septic patients by modulating insulin resistance and thus the prognosis of these patients. This justifies the investigator clinical research project on the relationship between the expression of PTP1B levels, glycemic status and prognosis evaluated by the SOFA score in patients with septic shock with multiple organ failure.
Looking for future studies?
Notify Me18 year and older
All sexes
Interventional
Not applicable
Rouen, France
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
PTP1B sampled and dosed during sepsis
Time frame: Day 5
Change from baseline in PTP1B level expression by biological analysis
Time frame: Day 5
Number of patients with organ failure
Time frame: Day 5
cumulative dose of insulin administered in the first 5 days of hospitalization
Time frame: Day 1
Evaluation of insulin resistance by biological analysis
Time frame: Day 5
Analysis of the variability in Blood glucose
Time frame: ICU discharge, day 28
ICU mortality at day 28
Time frame: Day 28
Mortality at day 28
Time frame: 10 days (average)
Mortality at hospital discharge, average of 10 days after surgical intervention
Time frame: Day 28
Duration of mechanical ventilation from admission to discharge
University Hospital, Rouen
Other
Acronym: SEPP1B
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07658014
Cardiovascular Diseases, Infections
Querétaro City, Querétaro, Mexico
View Trial DetailsNCT05900284
Acute Kidney Injury, Female Urogenital Diseases
Pittsburgh, Pennsylvania, United States
View Trial DetailsNCT05194189
Infections, Inflammation
Guanzhou, Guangdong, China
View Trial DetailsNCT07565649
Infections, Inflammation
Pamplona, Navarre, Spain
View Trial Details